Clinical article
Management and Outcome of Patients With Malignant Salivary Gland Tumors

https://doi.org/10.1016/j.joms.2005.03.006Get rights and content

Purpose

Refined imaging technology, the use of external beam radiation, neutron beam therapy, and chemotherapy, has altered management strategies for patients with salivary gland malignancies during the past 2 decades. Although treatment remains primarily surgical, optimal therapeutic regimens have yet to be fully realized. The purpose of this investigation is to report our experience with the management of patients with a variety of malignant salivary gland neoplasms that were treated with various combinations of surgery, radiation, and chemotherapy and to review treatment outcome in an effort to identify predictors of survival and locoregional control.

Materials and Methods

The records of all patients with malignant salivary gland tumors presenting for treatment at our institution between 1992 and 2002 were retrospectively reviewed. Variables were collected and outcome measures were defined in terms of overall survival, disease-free survival, and locoregional control. Descriptive statistics were compiled and statistically evaluated. Survival was described using the Kaplan-Meier method. Prognostic factors were assessed using the Cox proportional hazards model. Clinical and reconstructive factors were reviewed.

Results

Eighty-five patients (35 males and 50 females) ranging in age from 16 to 89 years (mean, 58.6 years) met the criteria for inclusion in the study. The majority of tumors were located in the parotid gland (n = 42), with a significant minority located in the minor salivary glands (n = 29), followed by the submandibular gland (n = 8) and the sublingual gland (n = 6). Mucoepidermoid carcinoma was the most common neoplasm (n = 40). More than half of the patients presented in early-stage disease (stage I = 36, stage II = 17, stage III = 8, stage IV = 25). All patients were treated with surgery as the primary modality. Neck dissection was performed in 29% of patients, and more than half (56%) were treated with adjuvant external beam radiation therapy to a dose of 50 to 70 Gy. Patients were, in general, immediately reconstructed at the time of ablation using composite free tissue transfer when appropriate, local/regional rotational flaps, or maxillary obturators. The disease-free survival rate and locoregional control rate at 5 years were 77% and 86%, respectively. Stage (P = .0017), grade (P = .00044), cervical lymph node metastasis (P = .03), and age (P = .01) proved to make a statistically significant contribution when describing outcome. Neither site (P = .5), the presence of positive margins (P = .3), nor perineural invasion (P = .7) had a significant impact on survival.

Conclusions

The treatment of salivary gland malignancies remains primarily surgical, although adjunctive radiotherapy may play an important role in those patients with advanced-stage disease. This study confirms the contributions of stage, grade, age, and cervical metastasis for describing survival. The benefits of combined modality therapy awaits prospective clinical trials.

Section snippets

Materials and Methods

The records of all patients with malignant salivary gland tumors presenting for treatment at Legacy Emanuel Hospital and Health Center (LEHHC) between 1992 and 2002 were retrospectively reviewed. Data were collected from the LEHHC cancer data registry and from individual physician chart notes. Variables collected included age, gender, tumor site, histologic diagnosis, grade, stage, symptoms, treatment, the presence of regional/distant metastasis, margin status, perineural/angiolymphatic

Results

Eighty-five patients met the criteria for inclusion in the study. Thirty-five of these patients were male and 50 were female, ranging in age from 16 to 89 years (mean, 58.6 years). The site of presentation was distributed as follows: parotid (n = 42 [50%]), submandibular gland (n = 8 [9%]), sublingual gland (n = 6 [7%]), and minor salivary glands (n = 29 [34%]) (Fig 1). Mucoepidermoid carcinoma was the most common neoplasm (n = 40 [47%]), followed by adenoid cystic carcinoma (n = 15 [18%]),

Discussion

The management of salivary gland malignancies remains primarily surgical. Refined imaging technology, recognition of the potential benefits of adjuvant radiation therapy, developments in neutron beam therapy, and the introduction of chemotherapeutic regimens have altered the various treatment strategies. Although the effect of radiation therapy was not specifically evaluated in this observational study, combined modality therapy appears to play an important role in the treatment of patients

References (39)

  • J. Medina

    Neck dissection in the treatment of cancer of major salivary glands

    Otolaryngol Clin North Am

    (1998)
  • S.N. Rogers et al.

    Health related quality of life after maxillectomyA comparison between prosthetic obturation and free flap

    J Oral Maxillofac Surg

    (2003)
  • R.H. Spiro

    Salivary neoplasmsOverview of a 35-year experience with 2807 patients

    Head Neck Surg

    (1986)
  • R.H. Spiro et al.

    Carcinoma of major salivary glands

    Arch Otolaryngol Head Neck Surg

    (1989)
  • P.L. Horn-Ross et al.

    Recent trends in the incidence of salivary gland cancer

    Int J Epidemiol

    (1991)
  • J.G. Armstrong et al.

    Malignant tumors of major salivary gland originA matched pair analysis of the role of combined surgery and postoperative radiotherapy

    Arch Otolaryngol Head Neck Surg

    (1990)
  • C. Calearo et al.

    Parotid gland carcinomaAnalysis of prognostic factors

    Ann Otol Rhinol Laryngol

    (1998)
  • H. Leverstein et al.

    Malignant epithelial parotid gland tumorsAnalysis and results in 65 previously untreated patients

    Br J Plast Surg

    (1998)
  • P. Kirkbride et al.

    Outcome of curative management of malignant tumours of the parotid gland

    J Otolaryngol

    (2001)
  • Cited by (212)

    • Diagnosis and Management of Pathological Conditions

      2023, Journal of Oral and Maxillofacial Surgery
    • The impact of interval between surgery and postoperative radiotherapy in major salivary gland carcinoma

      2022, Journal of the National Cancer Center
      Citation Excerpt :

      The proportion of adjuvant radiotherapy in patients with and without adverse features were 54%-84.5% and 17%,5 respectively. Radiotherapy following operation can improve local-regional control rate and survival in patients with adverse features, such as positive surgical margin, high-grade tumors, perineural invasion (PNI), T3-4 tumors, and positive lymph nodes.6,7 Despite the lack of prospective studies, postoperative radiotherapy (PORT) is strongly recommended for high-risk cases.

    View all citing articles on Scopus
    View full text